Published in:
Open Access
01-12-2018 | Research article
Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts
Authors:
Satoshi Hamanoue, Tatsuya Suwabe, Yoshifumi Ubara, Koichi Kikuchi, Ryo Hazue, Koki Mise, Toshiharu Ueno, Kenmei Takaichi, Kana Matsumoto, Kunihiko Morita
Published in:
BMC Nephrology
|
Issue 1/2018
Login to get access
Abstract
Background
Cyst infection is a common and serious complication of autosomal dominant polycystic kidney disease (ADPKD) that is often refractory. Carbapenems are frequently needed to treat to patients with refractory cyst infection, but little is known about the penetration of newer water-soluble carbapenems into cysts. This study investigated the penetration of meropenem (MEPM) into infected cysts in patients with ADPKD.
Methods
Between August 2013 and January 2014, 10 ADPKD patients (14 infected cysts) receiving MEPM at Toranomon Hospital underwent drainage of infected cysts and definite cyst infection was confirmed through detection of neutrophils by cyst fluid analysis. The serum concentration of MEPM was measured just after intravenous administration and was compared with that in fluid aspirated from infected cysts.
Results
In the patients undergoing cyst drainage, the mean serum MEPM concentration was 35.2 ± 12.2 μg/mL (range: 19.7 to 59.2 μg/mL, while the mean cyst fluid concentration of MEPM in the drained liver cysts (n = 12) or kidney cysts (n = 2) was 3.03 ± 2.6 μg/mL (range: 0 to 7.3 μg/mL). In addition, the mean cyst fluid/serum MEPM concentration ratio was 9.46 ± 7.19% (range: 0 to 18.8%). There was no relationship between the cyst fluid concentration of MEPM and the time until drainage after MEPM administration or between the cyst fluid/serum MEPM concentration ratio and the time until drainage.
Conclusion
These findings suggest that MEPM shows poor penetration into infected cysts in ADPKD patients.
Trial registration
This study was registered with the University Hospital Medical Information Network (UMIN) as “Penetration of meropenem into cysts in patients with autosomal dominant polycystic kidney disease (ADPKD)”, UMIN ID
000011292 on July 26th, 2013.